These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 20736511)

  • 1. Concentration-dependent inhibitory effect of irbesartan on renal uric acid transporters.
    Nakamura M; Anzai N; Jutabha P; Sato H; Sakurai H; Ichida K
    J Pharmacol Sci; 2010; 114(1):115-8. PubMed ID: 20736511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter.
    Iwanaga T; Sato M; Maeda T; Ogihara T; Tamai I
    J Pharmacol Exp Ther; 2007 Jan; 320(1):211-7. PubMed ID: 17043154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How does whisky lower serum urate level?
    Lu Y; Nakanishi T; Fukazawa M; Tamai I
    Phytother Res; 2014 May; 28(5):788-90. PubMed ID: 24022993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of fenofibrate on uric acid metabolism and urate transporter 1.
    Uetake D; Ohno I; Ichida K; Yamaguchi Y; Saikawa H; Endou H; Hosoya T
    Intern Med; 2010; 49(2):89-94. PubMed ID: 20075570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients.
    Hamada T; Ichida K; Hosoyamada M; Mizuta E; Yanagihara K; Sonoyama K; Sugihara S; Igawa O; Hosoya T; Ohtahara A; Shigamasa C; Yamamoto Y; Ninomiya H; Hisatome I
    Am J Hypertens; 2008 Oct; 21(10):1157-62. PubMed ID: 18670416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal Reabsorptive Transport of Uric Acid Precursor Xanthine by URAT1 and GLUT9.
    Arakawa H; Amezawa N; Kawakatsu Y; Tamai I
    Biol Pharm Bull; 2020; 43(11):1792-1798. PubMed ID: 33132325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of irbesartan, an angiotensin receptor blocker, on uric acid level and oxidative stress in high-risk hypertension patients.
    Chida R; Hisauchi I; Toyoda S; Kikuchi M; Komatsu T; Hori Y; Nakahara S; Sakai Y; Inoue T; Taguchi I
    Hypertens Res; 2015 Nov; 38(11):765-9. PubMed ID: 26178150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unique Binding Sites of Uricosuric Agent Dotinurad for Selective Inhibition of Renal Uric Acid Reabsorptive Transporter URAT1.
    Fujita K; Isozumi N; Zhu Q; Matsubayashi M; Taniguchi T; Arakawa H; Shirasaka Y; Mori E; Tamai I
    J Pharmacol Exp Ther; 2024 Jun; 390(1):99-107. PubMed ID: 38670801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans.
    Anzai N; Ichida K; Jutabha P; Kimura T; Babu E; Jin CJ; Srivastava S; Kitamura K; Hisatome I; Endou H; Sakurai H
    J Biol Chem; 2008 Oct; 283(40):26834-8. PubMed ID: 18701466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Stereoselective Metabolism, Inhibitory Effect on Uric Acid Uptake Transporters, and Pharmacokinetics of Lesinurad Atropisomers.
    Yang C; Zhou D; Shen Z; Wilson DM; Renner M; Miner JN; Girardet JL; Lee CA
    Drug Metab Dispos; 2019 Feb; 47(2):104-113. PubMed ID: 30442650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies of the renal effects of angiotensin II receptor blockade: the confounding factor of acute water loading on the action of vasoactive systems.
    Burnier M; Pechère-Bertschi A; Nussberger J; Waeber B; Brunner HR
    Am J Kidney Dis; 1995 Jul; 26(1):108-15. PubMed ID: 7611241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypouricemic Effects of Extracts from
    Han S; Wei R; Han D; Zhu J; Luo W; Ao W; Zhong G
    Biomed Res Int; 2020; 2020():2968135. PubMed ID: 32083126
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparative analysis of the efficacy of angiotensin II receptor blockers for uric acid level change in asymptomatic hyperuricaemia.
    Kim HS; Kim H; Lee SH; Kim JH
    J Clin Pharm Ther; 2020 Dec; 45(6):1264-1270. PubMed ID: 32737930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: a post-hoc analysis of the RENAAL and IDNT trials.
    Smink PA; Bakker SJ; Laverman GD; Berl T; Cooper ME; de Zeeuw D; Lambers Heerspink HJ
    J Hypertens; 2012 May; 30(5):1022-8. PubMed ID: 22388234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional cooperation of URAT1 (SLC22A12) and URATv1 (SLC2A9) in renal reabsorption of urate.
    Nakanishi T; Ohya K; Shimada S; Anzai N; Tamai I
    Nephrol Dial Transplant; 2013 Mar; 28(3):603-11. PubMed ID: 23291366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout.
    Tan PK; Liu S; Gunic E; Miner JN
    Sci Rep; 2017 Apr; 7(1):665. PubMed ID: 28386072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Flexible Naphthyltriazolylmethane-based Thioacetic Acids as Highly Active Uric Acid Transporter 1 (URAT1) Inhibitors for the Treatment of Hyperuricemia of Gout.
    Zhang X; Wu J; Liu W; Liu Y; Xie Y; Shang Q; Zhou Z; Xu W; Tang L; Wang J; Zhao G
    Med Chem; 2017; 13(3):260-281. PubMed ID: 27633583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. URAT1 inhibition by ALPK1 is associated with uric acid homeostasis.
    Kuo TM; Huang CM; Tu HP; Min-Shan Ko A; Wang SJ; Lee CP; Ko YC
    Rheumatology (Oxford); 2017 Apr; 56(4):654-659. PubMed ID: 28039413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor.
    Smith WB; Hall J; Berg JK; Kazimir M; Yamamoto A; Walker S; Lee CA; Shen Z; Wilson DM; Zhou D; Gillen M; Marbury TC
    Clin Drug Investig; 2018 Aug; 38(8):703-713. PubMed ID: 29949102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers.
    Sato M; Iwanaga T; Mamada H; Ogihara T; Yabuuchi H; Maeda T; Tamai I
    Pharm Res; 2008 Mar; 25(3):639-46. PubMed ID: 17674156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.